Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analysts hold a “Moderate Buy” consensus on Coya Therapeutics, with six buy ratings and one sell rating among seven brokers. The average 12-month price target is $15.33, well above the reported $4.64 share price.
• Coya reported a quarterly loss of $0.28 per share, beating the consensus estimate of a $0.35 loss, while revenue of $0.24 million exceeded expectations of $0.13 million. However, the company remains deeply unprofitable, with a negative net margin of 270.22%.
• Institutional ownership stands at 39.75%, with several hedge funds adding or initiating positions. Coya is developing therapies targeting fibrotic diseases and cancer, including the preclinical COY-001 and the advancing COY-002 programs.

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $15.3333.

COYA has been the subject of a number of research reports. Roth Capital restated a "buy" rating and set a $12.00 target price on shares of Coya Therapeutics in a report on Monday, August 24th. HC Wainwright reaffirmed a "buy" rating on shares of Coya Therapeutics in a report on Monday, August 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Coya Therapeutics in a research report on Friday, July 17th. Finally, Chardan Capital reissued a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, August 12th.

Coya Therapeutics Trading Up 5.9%

Shares of NASDAQ COYA opened at $4.64 on Tuesday. Coya Therapeutics has a twelve month low of $3.71 and a twelve month high of $7.75. The company has a market capitalization of $108.85 million, a price-to-earnings ratio of -4.34 and a beta of 0.61. The firm has a 50-day moving average of $4.66 and a two-hundred day moving average of $4.66.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.07. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%. The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.13 million. As a group, research analysts predict that Coya Therapeutics will post -1.34 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

Several hedge funds have recently modified their holdings of COYA. Allworth Financial LP increased its stake in Coya Therapeutics by 1,200.0% in the 2nd quarter. Allworth Financial LP now owns 13,000 shares of the company's stock worth $76,000 after purchasing an additional 12,000 shares in the last quarter. AXQ Capital LP acquired a new position in shares of Coya Therapeutics in the second quarter worth about $116,000. Long Corridor Asset Management Ltd acquired a new position in shares of Coya Therapeutics in the second quarter worth about $227,000. ADAR1 Capital Management LLC purchased a new position in shares of Coya Therapeutics in the first quarter worth approximately $161,000. Finally, Renaissance Technologies LLC increased its position in shares of Coya Therapeutics by 55.4% in the first quarter. Renaissance Technologies LLC now owns 103,964 shares of the company's stock worth $410,000 after acquiring an additional 37,064 shares in the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.